Uncategorized
BMJ investigation revives controversy over barriers to use of bevacizumab in UK
A new controversy on the long-standing question of use of Avastin vs. Lucentis in the treatment of retinal conditions was sparked in the U.K. by a two-part investigation recently published in the BMJ.BMJ investigations editor Deborah Cohen noted that no progress has been made in the U.K., by national agencies and NICE, toward removing barriers that restrict prescription and use of Avastin (bevacizumab, Genentech/Roche), although the cheaper drug could release more than £100 million for other patient services, despite advocacy by more than 100 clinical commissioning groups and patient associations.